News
President Trump’s proposed 25% tariff on pharmaceutical imports, largely from Ireland, could raise U.S. drug costs by nearly ...
Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...
Stocks closed higher Tuesday to extend a week-long rally as investors digested a flurry of earnings reports from major ...
Donald Ingber, MD, PhD; Miguel Forte, MD, PhD; Ali Pashazadeh, MRCS, MBA; and Adam Inche, PhD, MBA go behind the headlines to ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% ...
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...
Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...
21h
Zacks Investment Research on MSNRegeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales DownRegeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results